Kidney Stone Disease: Epigenetic Dysregulation in Homocystinuria and Mitochondrial Sulfur Trans-Sulfuration Ablation Driven by COVID-19 Pathophysiology

Area of Science:

• Nephrology
• Virology
• Metabolic Medicine
• Epigenetics

Background:

• The COVID-19 pandemic revealed diverse complications, including kidney issues and a potential link to kidney stone disease (KSD).
• Existing research often examines COVID-19's renal effects, epigenetic alterations, and metabolic pathways separately.

Purpose of the Study:

• To propose a novel framework connecting COVID-19-induced epigenetic reprogramming to disruptions in mitochondrial sulfur metabolism and kidney stone formation.
• To offer an integrated hypothesis explaining post-viral renal lithogenesis, considering viral methylation interference, sulfur amino acid imbalance, mitochondrial dysfunction, and microbiota changes.

Main Methods:

• Review of existing literature on COVID-19, epigenetics, sulfur metabolism, gut dysbiosis, and kidney stone pathogenesis.
• Analysis of proposed mechanisms linking SARS-CoV-2 infection to altered methylation, homocysteine levels, trans-sulfuration pathway impairment, and oxalate handling.
• Exploration of the role of gut dysbiosis in oxalate production and calcium oxalate stone formation.

Main Results:

• SARS-CoV-2 may interfere with host methylation, increasing homocysteine and impairing the trans-sulfuration pathway.
• Epigenetic and metabolic alterations can promote specific kidney stone subtypes via disrupted sulfur and oxalate handling.
• COVID-19-associated gut dysbiosis may increase oxalate production, driving calcium oxalate stone formation.

Conclusions:

• Integrated pathways involving viral methylation interference, sulfur metabolism imbalance, mitochondrial dysfunction, and gut microbiota changes may link COVID-19 to kidney stone disease.
• These mechanisms may accelerate the progression from acute kidney injury to chronic kidney stone disease post-infection.
• Targeting sulfur metabolism and redox pathways presents potential therapeutic strategies for virus-associated kidney stone disease.